The Food and Drug Administration delayed ruling on Sarepta Therapeutics Inc.'s
(Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen. The stock price surged $3.57 to $22.01.
FDA delays ruling on Sarepta's eteplirsen
May 25, 2016 at 13:47 PM EDT
